REGENERON PHARMACEUTICALS, INC. (REGN) Form 8-K — Oct 30, 2026
Regeneron reported Q3 2026 revenues of $5.1 billion, up 36% year over year, with GAAP EPS of $18.45 (+35%) and non-GAAP EPS of $20.07 (+70%). Growth was driven by record net sales for Dupixent ($6.5B global, +35%), EYLEA HD ($699M US, +62%), and Libtayo ($550M global, +51%), plus a 68% jump in Sanofi collaboration revenue after full repayment of the Development Balance. Legacy EYLEA US sales fell 41% on competitive pressure. Regeneron also expanded its Sanofi antibody collaboration with a $1.0 billion upfront (to be booked in Q4 2026) and up to $7.0 billion in additional milestones, and the FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva.
Key figures
- Eps
- 18.45
- Revenue
- 5116
- Guidance
- Updated FY2026 guidance: GAAP R&D $6.600-$6.735B (raised), non-GAAP R&D $6.050-$6.150B, GAAP SG&A $2.730-$2.860B (lowered), non-GAAP gross margin ~86%, GAAP ETR ~14%, capex $1.050-$1.100B
- Net Income
- 1949
- Total Debt
- 1,987.0 million long-term debt
- Revenue Yoy
- 36%
- Total Assets
- 44,405.2 million
- Cash Position
- 18,858.5 million (cash and marketable securities)
- Shares Outstanding
- 101.7 million basic weighted average
- Non gaap eps yoy
- 70%
- Dividend per share
- $0.94
- Eylea us net sales
- $400 million (-41%)
- Gaap net income yoy
- 33%
- Non gaap eps q3 2026
- 20.07
- Eylea hd us net sales
- $699 million (+62%)
- Libtayo global net sales
- $550 million (+51%)
- Sanofi expansion upfront
- $1.0 billion
- Buybacks nine months 2026
- $2.3 billion
- Dupixent global net sales
- $6.5 billion (+35%)
- Buyback capacity remaining
- $2.2 billion
- Free cash flow nine months
- $2,904.3 million
- Sanofi collaboration revenue
- $2,724 million (+68%)
- Sanofi expansion potential milestones
- up to $7.0 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.